Raymond James Financial
LCTX icon

Raymond James Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Raymond James Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133K Buy
83,984
+3,799
+5% +$6.41K ﹤0.01% 4977
2025
Q4 		$134K Sell
80,185
-10,196
-11% -$17.6K ﹤0.01% 4875
2025
Q3 		$153K Buy
90,381
+21,001
+30% +$24.9K ﹤0.01% 4679
2025
Q2 		$63K Buy
69,380
+40,009
+136% +$23.7K ﹤0.01% 5088
2025
Q1 		$13.3K Sell
29,371
-5,000
-15% -$2.93K ﹤0.01% 4762
2024
Q4 		$17.3K Buy
+34,371
New +$25.2K ﹤0.01% 4739

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's LCTX Position: Q1 2026 in Review

Raymond James Financial increased its Lineage Cell Therapeutics (LCTX) stake by 4.7% in Q1 2026, buying an estimated $6.41K and bringing the position to 83,984 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #4977.

Raymond James Financial first reported a position in LCTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $153K in Q3 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Raymond James Financial held 83,984 shares of Lineage Cell Therapeutics worth $133K as of Q1 2026.
  • Raymond James Financial bought 3,799 Lineage Cell Therapeutics shares in Q1 2026, an estimated $6.41K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4977 holding.
  • Raymond James Financial first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Lineage Cell Therapeutics position peaked at $153K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.